Our people

Krystal employees are our most valuable resource for continued success.

Anne Rogel - Accountant
Anne Rogel is an accountant who provides accounting and HR support to the Krystal team. Anne is a CPA and has 11+ years of accounting experience including 3.5 years as the assistant controller of a small oil and gas company and 7 years in public accounting as an auditor. Anne received her B.S. in Accounting from the University of Pittsburgh. Outside of work Anne spends most of her time with her husband and 2 young children.

Anne Rogel

Avijit Majumdar - Senior Scientist
Avijit leads the preclinical discovery efforts at Krystal Biotech. Prior to joining Krystal, he supported preclinical development of gene based therapies within the Human Therapeutics Program at Intrexon Corporation. Avijit received his doctoral degree in Cell and Molecular Biology from Kent State University, Ohio and his postdoctoral training from Case Western Reserve University and the University of Texas MD Anderson Cancer Center. Outside of work, he loves to spend time with his family and watching his favorite sports.

Avijit Majumdar
Senior Scientist

Court Freedman - Scientist
Court Freedman is a molecular biologist and biochemist with 10+ years of experience in genome modification and the biochemical characterization of proteins. He received his Ph.D. in Microbiology and Immunology at the Virginia Commonwealth University School of Medicine where he studied the molecular genetics and physiology of spirochetes. After a postdoc at the University of Pittsburgh, studying bacterial genetics and the cellular activity of bacterial toxins, Court joined the team at Krystal Biotech where he supports discovery and platform development. In his free time, Court enjoys embarking on culinary adventures at home and around town, cheering for his favorite sports teams, traveling, and reading postmodern fiction.

Court Freedman

Dan Janney - Board Member
Dan Janney is the Managing Partner of Alta Partners. Dan joined Alta at its founding and has over 20 years of successful early stage investing experience in life sciences. His focus on working with exceptional entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of over 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions. Dan is currently on the board of directors of several public and private companies, including Esperion Therapeutics (NASDAQ:ESPR), Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve (OTC:VIVMF). In addition, he led AltaÕs investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ: CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker), Neothetics (NASDAQ:NEOT), and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).

Dan Janney
Board Member

David Reitsma - Quality Control Specialist
David is an experienced quality professional with a background in both laboratory and manufacturing systems. He has spent 12 years in the commercial environmental laboratory business and 15 years in the pharmaceutical industry where he gained expertise in GMP, GLP, and GCP. David is excited for the opportunity to apply this experience at Krystal by helping to develop and implement GMP compliant quality systems, laboratory space, and manufacturing facilities. David is an avid reader, a serious puck-head, and a certified coffee snob.

David Reitsma
Quality Control Specialist

Dino A. Rossi - Board Member
Dino A. Rossi is a results oriented, hands-on senior executive with proven experience initiating and leading organizations through the chaos and ambiguity of change. Strengths in defining and building management teams to execute plans and build shareholder value. Excellent experience in international relationships, LBOÕs, directing operations, research and development and commercial groups. Special ability to motivate and manage employees and Board members with intuitive business understanding. Retired as Interim President of Elite Comfort Solutions (ECS) in January, 2017, after working with PE group, Arsenal Capital Partners, to form this $450M revenue technology leading polyurethane foam entity via 4 acquisitions in a 6-month period, beginning in January 2016. Successfully transitioned this role to a permanent CEO and is now Board Advisor to Arsenal / ECS. President and CEO of Balchem Corporation (BCPC-Nasdaq) from 1997 thru 2015, and Chairman of the Board of Directors from 2007 thru 2016. While at Balchem lead significant strategic changes and growth of the business ($28M to $550M in revenue) and increased Net Income driving the stock market capitalization from $20M to $1.8B, focused on specialty chemicals for human and animal health, nutritional supplements and certain industrial end markets. Rebuilt the management team, Board of Directors and executed 6 strategic acquisitions and improved technologies that positively altered the Balchem business direction. Wall Street Journal, January 2016, did an analysis and wrote an article on the best performing stock over the last 30 years and in fact it was Balchem , up 107,099% . Prior to this, Mr. Rossi was Chief Financial Officer and Treasurer from April 1996. He was Vice President, Finance and Administration of Norit Americas Inc., a wholly-owned subsidiary of Norit N.V., a Dutch chemicals company, from January 1994 to February 1996, and Vice President, Finance and Administration of Oakite Products Inc., a specialty chemicals company, from 1987 to 1993. This company was on the NYSE until acquired by PE group Carlyle. Mr. Rossi worked with Carlyle as the CFO until the company was sold to a large German conglomerate, Metalgeselschaft. Prior to this role Mr. Rossi worked for Diamond Shamrock progressing through various accounting and financial roles in NA and Canada.

Dino A. Rossi
Board Member

Doug Norby - Board Member
Douglas Norby has been a director of Alexion since September 1999 and was appointed lead independent director in October 2014. In addition to serving on AlexionÕs Board, he has held positions of increasing responsibility at many companies, including serving as Senior Vice President and Chief Financial Officer of Tessera, Inc., a provider of intellectual property for advanced semiconductor packaging, and as Senior Vice President and Chief Financial Officer of Zambeel, Inc., a data storage systems company. Mr. Norby has also served as Senior Vice President and Chief Financial Officer of Novalux, Inc., a manufacturer of lasers for optical networks, as Executive Vice President and Chief Financial Officer of LSI Logic Corporation, a semiconductor company, as Senior Vice President and Chief Financial Officer of Mentor Graphics Corporation, a software company, and as President and Chief Operating Officer at Lucasfilm, Ltd., an entertainment company. His pharmaceutical experience includes serving as President of Pharmetrix Corporation, a drug delivery company, and as Senior Vice President and Chief Financial Officer of Syntex Corporation, a pharmaceutical company. Mr. Norby received a bachelor's degree in Economics from Harvard University and an MBA from Harvard Business School.

Doug Norby
Board Member

Joshua Fantini - Associate Director, Quality Assurance
Joshua has over 10 years of experience in quality assurance and quality control activities in the pharmaceutical and medical device industries. Starting his career at a pharmaceutical contract manufacturing organization, he developed a background in quality control and eventually moved into the quality assurance world where he was responsible for cGMP regulatory compliance, customer satisfaction, and overall Quality. Moving to a medical device company, he developed and implemented Quality systems to support GMP activities. Joshua has experience in compliance with FDA (e.g., 21 CFR Parts 11, 210, 211, and 820), EMA, and cGMP regulations, and ISO 9001, 13485, 14001, and 27001 standards. Outside of work, Joshua is in search of a great pie (pizza or fruit), brew, or ice cream spot.

Joshua Fantini
Associate Director, Quality Assurance

Kat Tuminello - Human Resources and Office Manager
Kat (Katherine) Tuminello is a muti-talented muti-tasker who provides administrative and HR support to the Krystal team. Prior to joining Krystal, Kat worked in various administrative capacities in the non-profit sector, and as a Clinical Research Specialist at Western Psychiatric Institute and Clinic. Kat received her B.S. degree in Psychology from the University of Pittsburgh. Outside of work, Kat plays on a baseball team and loves to travel.

Kat Tuminello
Human Resources and Office Manager

Kirti Ganorkar - Board Member
Kirti Ganorkar is Executive Vice President and Head, Global Business Development at Sun Pharma. Sun Pharma is the worldÕs fourth largest specialty generic pharmaceutical company, producing a comprehensive portfolio of products targeting a wide spectrum of chronic and acute treatments. SunÕs manufacturing capabilities span generics, branded generics, difficult-to-make technology intensive products, over-the-counter (OTC), anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates, and with >45 manufacturing sites and >2000 marketed products, they have a presence in more than 150 countries.

Kirti Ganorkar
Board Member

Krish Krishnan - Chairman and Chief Executive Officer
Krish Krishnan is an accomplished biotech executive. He was specifically involved in two successful IPOs (COO/CFO of New River Pharmaceuticals, Inc., NASDAQ: NRPH) and COO of Intrexon Corporation, Inc., NYSE:XON), approval of the blockbuster drug Vyvanse (for ADHD in 2007) and the sale of New River Pharmaceuticals, Inc. to Shire Pharmaceuticals, plc for $2.6 billion. He served as the CEO of Pinnacle Pharmaceuticals, Inc. and advanced a potential treatment for urinary tract infection from discovery to Phase II. He has served as Board member for Biotie Therapies Oyi (BTH1V:Helsinki, NASDAQ: BITI), a specialized drug development company in Finland and Thar Pharmaceuticals,Inc. prior to its sale to Grunenthal GmbH in 2017. Previously, Krish served as a Managing Principal of (a pharmaceutical B2B marketplace) that was sold to Ariba in 2001 for $500m. Krish started his career as a Senior Engineer at E.I.Dupont de Nemours. Krish has an undergraduate degree from the Indian Institute of Technology and a graduate degree in Finance from The Wharton School at University of Pennsylvania.

Krish Krishnan
Chairman and Chief Executive Officer

Lauren Regula - Scientist
Lauren Regula is a molecular biochemist with training in the fields of virology, immunology, and biophysics. She received her Ph.D in Biomedical Sciences from Albert Einstein College of Medicine, where she studied mechanisms for neutralizing both HIV-1 and Ebolavirus and structurally characterized key proteins involved in viral entry. At Krystal Biotech, she supports discovery, preclinical, and platform development. Outside of work, Lauren is a dance and music aficionado and spends her free time tap dancing, or playing guitar, ukulele, and bass!

Lauren Regula

Mark O’'Malley - Scientist
Mark O'Malley is a molecular virologist with over 30 years of experience developing viral vectors for gene therapy applications. Prior to joining Krystal Biotech, he was involved in the development of viral vectors, from viral genome engineering through safety evaluation in early phase clinical trials. At Krystal, Mark is critically involved in platform engineering and also supports preclinical development.After a long day in the lab, Mark enjoys nothing more than spending time with his wife and son (and our two great dogs!) taking walks or just watching old movies at home. He and his wife run a small antiques business in their spare time, so they love flea markets, garage sales, and any time they get a chance to dig around an attic for all things "old, interesting, and dusty".

Mark O’'Malley

Peipei Zhang - Scientist
Peipei Zhang has 15 years of clinical and research experience in the field of reconstructive surgery with a focus on the application of novel technologies for the treatment of chronic and non-healing dermatological wounds. She received her M.D. and Ph.D. at Medical School of Chinese PLA in Beijing, China, and practiced as an Attending Physician in the Burn Institute at PLA General Hospital, the largest burn center in China. She conducted basic research in skin wound healing and regeneration as research fellows at the University of Pittsburgh Medical Center and Weill Cornell Medical College successively. After a postdoc at the National Institutes of Health, researching molecular biology, cell biology and mouse models of gap junction proteins in skin, Peipei joined the team at Krystal Biotech where she is responsible for the development and execution of complex in vitro, ex vivo, and in vivo studies to support target identification and advancement of drug discovery projects. In her spare time, Peipei likes to stay with family and travel around in order to experience different cultures.

Peipei Zhang

Pooja Agarwal - Vice President, Product Development
Pooja Agarwal provides technical and strategic leadership to the Research and Development group at Krystal, and is critically involved in all aspects of product development from concept to clinic.Prior to joining Krystal, she was Senior Director, Human Therapeutics, at Intrexon Corporation where she managed the preclinical development of several gene therapy programs in Ophthalmology, Oncology, and Neuropathic Diseases, as well as strategic alliances with internal and external partnerships. Pooja holds a PhD in Biomedical Sciences from University of California San Francisco, a Masters of Science in Molecular and Medical Genetics from University of Toronto, and a Bachelors of Science (Summa Cum Laude) in Biochemistry from McMaster University. When not immersed in work, she loves hiking and spending time with her family, or curling with a good book and a glass of wine.

Pooja Agarwal
Vice President, Product Development

S.D. Yogesha - Associate Director, Manufacturing
Yogesha leads process development and manufacturing efforts at Krystal. He received his PhD in Biotechnology from National Centre for Cell Science, Pune, India and got trained as X-ray Crystallographer during his postdoc. He has more than a decade of experience in molecular biology, biochemistry, and structural Biology. Prior to Krystal, he did Downstream Process Development at Cytovance Biologics, Oklahoma City, OK. He likes to spend his free time with family and watching his favorite sports.

S.D. Yogesha
Associate Director, Manufacturing

Sarah Coghlan - Senior Research Associate
Sarah Coghlan is a molecular biologist and analytical chemist with over eight years of experience in translational and clinical research in diverse lab environments ranging from non-GLP to CLIA, GLP, and cGMP-compliant. At Krystal, she leads downstream process development, and provides molecular support for platform and preclinical development programs. In her spare time, Sarah enjoys playing volleyball and spending time with her greyhound, Beaker.

Sarah Coghlan
Senior Research Associate

Schuyler Vincent - Sr. Director, Regulatory and Clinical Operations
Schuyler Vinzant has worked in drug development for about 18 years and has spent the most recent 5 years developing gene therapies. In the gene therapy arena he has successfully filed 3 INDs, 2 RAC submissions and several special program applications inherent to the development of orphan gene therapies. His primary focus for the last 3 years was the regulatory and clinical development of an autologous genetically modified cell therapy for RDEB. Prior to joining Krystal, Schuyler served in increasing roles in small to mid-size biotech companies, working on a broad range of indications, with a primary focus on clinical and regulatory operations. Outside of work Schuyler enjoys racquetball and bass guitar.

Schuyler Vincent
Sr. Director, Regulatory and Clinical Operations

Suma Krishnan - Founder and Chief Operations Officer
Suma Krishnan has 25 years of drug development experience and has delivered on multiple gene therapy programs from discovery to the clinic as Head of Therapeutics at Intrexon Corporation (NYSE:XON). Previously, she led the discovery, development, and approval of Vyvanse (blockbuster drug to treat ADHD) as SVP, Product Development at New River Pharmaceuticals. Prior to that, Suma advanced approval of Adderall XR and Fosrenol at Shire. She began her career as a discovery scientist for Janssen Pharmaceuticals, Inc. Suma has over 20 publications and 20 issued US patents. She received her Master of Science in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research, and an undergraduate degree in Organic Chemistry from Ferguson University.

Suma Krishnan
Founder and Chief Operations Officer

Suresh Ramasamy - Senior Scientist
Suresh Ramasamy is a structural and synthetic biologist with 15+ years of experience in soluble and membrane protein expression, purification and structural characterization. He supports down stream processing and formulation development efforts at Krystal Biotech. He received his Ph.D in structural biology at National chemical laboratory, India. Prior to Krystal Biotech, Suresh worked as technical consultant at various biotech firms. In his free time he likes to travel, trekking and listen music.

Suresh Ramasamy
Senior Scientist

Tony Riley - Chief Financial Officer
Tony has over 20 years of financial management experience including as partner at the CFO Network LLC, a consulting firm with clients that included public companies (McKesson, CareDx, NetApp, Trimble Navigation, Aclara Biosciences, RingCentral, Pattern Energy) and venture-backed companies (FLX Bio, Harpoon Therapeutics, Rimini Street, Mobileum). His work was heavily focused on M&A and SEC reporting. Previously, he was CFO at Avanex Corporation and Corporate Controller at Kosan Biosciences. Prior to that, Tony held a variety of roles at Troy Chemical, a specialty chemicals company based in New Jersey. Tony has extensive international experience and has lived in 4 countries. He received a B.Sc. from the University of Bristol and an M.B.A. from the University of Chicago Booth School of Business. Mr. Riley is a Certified Public Accountant (inactive) in the state of California. Tony enjoys marathon running and one day would like to run all the marathon majors.

Tony Riley
Chief Financial Officer

Trevor Parry - Associate Director, Patent and Corporate Affairs
Trevor Parry manages Krystal's intellectual property portfolio, providing patent prosecution and counseling in both the US and foreign jurisdictions, as well as advising on IP management and licensing. Prior to joining Krystal, Trevor was a patent agent in Morrison & Foerster LLP's Life Sciences Group, with a focus on gene and antibody therapeutics, vaccines, and pharmaceutical manufacturing. Trevor's practice included coordinating patent prosecution and strategies in the US, Europe, Asia, and Australia. Trevor has extensive experience in patent drafting and prosecution, IP due diligence and landscape reviews, and freedom-to-operate analyses. Trevor received a B.S. in biochemistry/cell biology, as well as an M.S. in biology with an emphasis on biochemistry, from the University of California, San Diego. Trevor received his Ph.D. in molecular biology from the Department of Microbiology and Immunology at the University of California, San Francisco. His doctoral research focused on innate immunity and the interplay between bacterial pathogens and host cell signaling, incorporating work in bacterial and mammalian genetics with large-scale animal studies. In his off time, Trevor loves to travel, fly fish, and homebrew beer. Bar admission: U.S. Patent & Trademark Office

Trevor Parry
Associate Director, Patent and Corporate Affairs